Tag: breast cancer
Sacituzumab Govitecan Increases PFS for Patients With Most Common Type of...
Treatment with sacituzumab govitecan (Trodelvy®; Gilead Sciences), an antibody-drug conjugate (ADC), resulted in longer progression-free survival (PFS) compared to physician’s choice of chemotherapy in...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...
The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...
TULIP® Study in Patients With HER2+ Unresectable Locally Advanced or Metastatic...
Results from the Phase III TULIP® study, a multi-center, open-label, randomized clinical trial of Trastuzumab Duocarmazine (SYD985; Byondis Biopharmaceuticals), a next-generation antibody-drug conjugate confirms...
Trastuzumab deruxtecan Launced in Japan for Patients with HER2 Positive Unresectable...
This week Daiichi Sankyo announced the launch of trastuzumab deruxtecan (Enhertu®), a HER2 directed antibody-drug conjugate (ADC), in Japan.
The newly approved agent is a...
Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab...
Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...
Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...
Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...
Trastuzumab Duocarmazine Granted U.S. FDA Fast Track Designation for Pre-treated HER2+...
The United States Food & Drug Administration (FDA) has granted Fast Track designation for The Netherlands-based Synthon Biopharmaceuticals investigational anti-HER2 antibody-drug conjugate or ADC...
Phase I Study of Single Agent ZW25 Continues to Show Clinical...
Data covering the completed dose escalation portion of its Phase I study of ZW25 (Zymeworks) , a novel Azymetric™ bispecific antibody targeting two distinct...
